Recent Updates
Recently added Catalysts
REGN

REGENERON REPORTS SECOND QUARTER FINANCIAL AND OPERATING RESULTS BLA Filing for Auto-Inflammatory Diseases Planned for Early 2007 Two Antibody Candidates from VelocImmune Program to Enter Clinical Trials Each Year Beginning in 2007

Thursday, August 3, 2006 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: REGENERON REPORTS SECOND QUARTER FINANCIAL AND OPERATING RESULTS BLA Filing for Auto-Inflammatory Diseases Planned for Early 2007 Two Antibody Candidates from VelocImmune Program to Enter Clinical Trials Each Year Beginning in 2007

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+42%
120-day peak, hindsight
Typical move
2.7%
average across 15 past catalysts
Lead asset
REGN7508
Phase 3 · Venous Thromboembolism

Full Press Release Details

REGENERON REPORTS SECOND QUARTER FINANCIAL AND OPERATING RESULTS BLA Filing for Auto-Inflammatory Diseases Planned for Early 2007 Two Antibody Candidates from VelocImmune Program to Enter Clinical Trials Each Year Beginning in 2007.

Biotech snapshot

Cash runway
$17823M liquidity · $0M/mo burn
Low dilution risk
Lead asset
REGN7508Phase 3
Venous Thromboembolism →

Catalyst track record

+42%
best trade around REGN's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for REGN.

See every catalyst's timing & PoA →